Telomere length at diagnosis of chronic phase chronic myeloid leukemia (CML-CP) identifies a subgroup with favourable prognostic parameters and molecular response according to the ELN criteria after 12 months of treatment with nilotinib.
作者信息
Wenn K, Tomala L, Wilop S, Vankann L, Hasenbank C, Frank O, Hochhaus A, Giles F J, Lange T, Müller M C, Koschmieder S, Beier F, Ziegler P, Brümmendorf T H
机构信息
Department of Hematology, Oncology, Hemostaseology and Stem Cell Transplantation, Medical Faculty, RWTH Aachen University, Aachen, Germany.
Novartis Pharma GmbH, Nürnberg, Germany.
出版信息
Leukemia. 2015 Dec;29(12):2402-4. doi: 10.1038/leu.2015.245. Epub 2015 Sep 15.
PMID:26369986
Abstract
摘要
Zotero 插件